Cogent Biosciences

US · COGT #2052 by market cap Listed 2016

30.14 -0.24 -0.79%

Live - 5344 symbols - heartbeat 72s ago · 2026-10-08 07:53

Pre-market 30.10 -0.14%

After-hours 30.14 0.00%

Market cap: 5.23B
P/E (TTM): -13.95
P/B: 11.18
EPS: -2.16
Div yield: 0.00%
52W pos: 55%

Reader sentiment Are you bullish or bearish on COGT?

Anonymous reader poll. Unscientific, not investment advice.

About Cogent Biosciences

Cogent Biosciences, Inc. is a biotechnology company, which engages in the development of precision therapies for genetically defined diseases. It focuses on CGT9486, a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation and other mutations in KIT exon 17. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Waltham, MA.

Founded: 2014
CEO: Mr. Andrews R. Robbins, M.B.A.
Employees: 258
Headquarters: Waltham, Massachusetts, United States of America
Fiscal year end: 12-31
Website: cogentbio.com

Company profile

Exchange: US
Symbol: COGT
Market-cap rank: #2052
Listing date: 2016-09-26
Market cap: 5.23B
Float cap: 5.20B
Shares out: 173.52M
Float shares: 172.52M

Sectors & themes

Biotechnology Fractional Shares JP

Browse all sectors & themes

Quote time 2026-10-08 07:53:17 · For reference only, not investment advice and not tailored to your situation.